163 related articles for article (PubMed ID: 38667461)
1. Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver Biopsy.
Kawano M; Yano Y; Yamamoto A; Yasutomi E; Inoue Y; Kitadai J; Yoshida R; Matsuura T; Shiomi Y; Ueda Y; Kodama Y
Diagnostics (Basel); 2024 Apr; 14(8):. PubMed ID: 38667461
[TBL] [Abstract][Full Text] [Related]
2. Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort.
Hountondji L; Ferreira De Matos C; Lebossé F; Quantin X; Lesage C; Palassin P; Rivet V; Faure S; Pageaux GP; Assenat É; Alric L; Zahhaf A; Larrey D; Witkowski Durand Viel P; Riviere B; Janick S; Dalle S; Maria ATJ; Comont T; Meunier L
JHEP Rep; 2023 Jun; 5(6):100719. PubMed ID: 37138674
[TBL] [Abstract][Full Text] [Related]
3. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors.
De Martin E; Michot JM; Rosmorduc O; Guettier C; Samuel D
JHEP Rep; 2020 Dec; 2(6):100170. PubMed ID: 33205034
[TBL] [Abstract][Full Text] [Related]
4. Histological Characteristics and Management of Hepatitis on Immune Checkpoint Inhibitors: A Retrospective Descriptive Study.
Parlati L; Marcin K; Terris B; Vallet-Pichard A; Corouge M; Hollande C; Sogni P; Mallet V; Pol S
J Clin Med; 2023 May; 12(11):. PubMed ID: 37297945
[TBL] [Abstract][Full Text] [Related]
5. The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity.
Robles-Diaz M; Garcia-Cortes M; Medina-Caliz I; Gonzalez-Jimenez A; Gonzalez-Grande R; Navarro JM; Castiella A; Zapata EM; Romero-Gomez M; Blanco S; Soriano G; Hidalgo R; Ortega-Torres M; Clavijo E; Bermudez-Ruiz PM; Lucena MI; Andrade RJ; ;
Liver Int; 2015 Nov; 35(11):2474-82. PubMed ID: 25809419
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic guide for immune checkpoint inhibitor-induced liver injury.
Ito T; Takeuchi Y; Mizuno K; Imai M; Yoshimaru Y; Abe K; Abe M; Matsuura T; Yokode M; Shiokawa M; Kodama Y; Komuta M; Harada K; Tanaka A
Hepatol Res; 2024 Jun; ():. PubMed ID: 38884591
[TBL] [Abstract][Full Text] [Related]
7. Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor.
Sawada K; Hayashi H; Nakajima S; Hasebe T; Fujiya M; Okumura T
J Gastroenterol Hepatol; 2020 Jun; 35(6):1042-1048. PubMed ID: 31752049
[TBL] [Abstract][Full Text] [Related]
8. Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors.
Parlati L; Sakka M; Retbi A; Bouam S; Hassani L; Meritet JF; Rufat P; Bonnefont-Rousselot D; Batista R; Terris B; Bellanger A; Thabut D; Vozy A; Spano JP; Coriat R; Goldwasser F; Aractingi S; Sogni P; Pol S; Mallet V; ;
JHEP Rep; 2023 Dec; 5(12):100880. PubMed ID: 38074948
[TBL] [Abstract][Full Text] [Related]
9. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations.
Kleiner DE; Chalasani NP; Lee WM; Fontana RJ; Bonkovsky HL; Watkins PB; Hayashi PH; Davern TJ; Navarro V; Reddy R; Talwalkar JA; Stolz A; Gu J; Barnhart H; Hoofnagle JH;
Hepatology; 2014 Feb; 59(2):661-70. PubMed ID: 24037963
[TBL] [Abstract][Full Text] [Related]
10. [Clinical and pathological features in 138 cases of drug-induced liver injury].
Lai RT; Wang H; Gui HL; Ye MZ; Dai WJ; Xiang XG; Zhao GD; Wang WJ; Xie Q
Zhonghua Gan Zang Bing Za Zhi; 2012 Mar; 20(3):185-9. PubMed ID: 22475136
[TBL] [Abstract][Full Text] [Related]
11. Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience.
da Silva JA; Falcão D; Cardoso C; Pires AL; Araújo A; Castro-Poças F
Ann Hepatol; 2021 Dec; 26():100561. PubMed ID: 34653687
[TBL] [Abstract][Full Text] [Related]
12. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
[TBL] [Abstract][Full Text] [Related]
13. Hepatobiliary and Pancreatic Adverse Events.
Zhang HC; Wang LS; Miller E
Adv Exp Med Biol; 2021; 1342():339-355. PubMed ID: 34972973
[TBL] [Abstract][Full Text] [Related]
14. Risk factors and prognostic role of renal adverse event in patients receiving immune checkpoint inhibitor therapy: analysis of data from a retrospective cohort study.
Bao Z; Luo L; Xu T; Yang J; Lv M; Ni L; Sun X; Chen W; Zhou L; Wang X; Xiang Y; Gao B
Ann Transl Med; 2022 Sep; 10(18):967. PubMed ID: 36267724
[TBL] [Abstract][Full Text] [Related]
15. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
[TBL] [Abstract][Full Text] [Related]
16. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies.
Mizuno K; Ito T; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Kawashima H; Inukai Y; Toyoda H; Yokota K; Hase T; Maeda O; Kiyoi H; Nagino M; Hibi H; Kodera Y; Fujimoto Y; Sone M; Gotoh M; Ando Y; Akiyama M; Hasegawa Y; Fujishiro M
J Gastroenterol; 2020 Jun; 55(6):653-661. PubMed ID: 32124082
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology and Management of Drug-induced Liver Injury: Importance of the Updated RUCAM.
Kobayashi T; Iwaki M; Nogami A; Yoneda M
J Clin Transl Hepatol; 2023 Oct; 11(5):1239-1245. PubMed ID: 37577239
[TBL] [Abstract][Full Text] [Related]
18. Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies.
Ito T; Ishigami M; Yamamoto T; Mizuno K; Yamamoto K; Imai N; Ishizu Y; Honda T; Kawashima H; Yasuda S; Toyoda H; Yokota K; Hase T; Nishio N; Maeda O; Kato M; Hashimoto N; Hibi H; Kodera Y; Sone M; Ando Y; Akiyama M; Shimoyama Y; Fujishiro M
Hepatol Int; 2021 Oct; 15(5):1278-1287. PubMed ID: 34373964
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review.
Ueno M; Takabatake H; Hata A; Kayahara T; Morimoto Y; Notohara K; Mizuno M
Cancer Rep (Hoboken); 2022 Sep; 5(9):e1624. PubMed ID: 35575047
[TBL] [Abstract][Full Text] [Related]
20. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]